Site Search
Professionals 48 results
Capabilities 32 results
Practice Area
Derivatives & Structured Products
Winston represents swap dealers, major swap participants, financial intermediaries, hedge funds, national exchanges, and end-users in a broad array of derivative transactions ranging from highly structured transactions to more traditional trading or hedging transactions, and in regulatory and enforcement issues related to commodities and derivatives.
Practice Area
Our structured finance group is widely recognized as a leader, encompassing Esoteric Finance, Residential Asset Finance and Securitization, and CLOs/Fund Finance. Positioned prominently at the forefront of the industry, our team boasts extensive experience across a broad spectrum of assets, with a particular focus on bespoke structures and emerging and/or “esoteric” assets, including residential and commercial PACE, RMBS, and CMBS; aircraft, vessel, and railcar finance; FinTech and marketplace lending; CLOs; specialty finance; consumer and business lending; energy structured finance (including solar finance and reserve-based finance); derivatives and structured products; lease and operating asset finance; trade receivables; litigation settlement financing; and life settlements.
Practice Area
Securities, M&A & Corporate Governance Litigation
In today’s market, litigators with experience in securities, corporate governance, and M&A-related (collectively, “securities litigation”) matters need to leverage their broad experience to serve as both advocate and as counsel and strategist, focused on helping clients to overcome not just a legal issue but a collective business problem. Given the frequent interplay between things such as corporate-control transactions, public offerings, activist shareholders, the use of complex derivatives and other financial instruments, bad news impacting stock performance, regulatory inquiries and investigations, and insurance coverage, strategic and tactical litigation decisions can have a wide-ranging impact on the success of a given transaction, as well as on companies, their boards, senior management, and advisors.
Experience 4 results
Experience
|September 20, 2021
Socieded Química y Minera de Chile S.A. US$700M 3.500% Notes due 2051 ("Green" Bond Offering)
Winston & Strawn LLP represented Socieded Química y Minera de Chile S.A. (SQM) in connection with its first "green" bond offering of US$700M principal amount of 3.500% Notes due 2051 (the “Green Bonds”). The Green Bonds were sold in an offering exempt from registration pursuant to Rule 144A and Regulation S. The proceeds of the Green Bonds will be used to finance or refinance recently completed or future eligible green projects with respect to lithium production capacity expansion for applications related to clean transportation and energy efficiency. Disbursements may cover project expenditures for up to 36 months preceding the issuance of the Green Bonds and until their maturity date. BofA Securities, Inc.; Goldman Sachs & Co. LLC; J.P. Morgan Securities; and Santander Investment Securities Inc. acted as initial purchasers of the Green Bonds. SQM is a Chile-based global leader in the production of specialty plant nutrients, iodine and derivatives, lithium and derivatives, potassium, and certain industrial chemicals.
Experience
|June 21, 2021
Calvin Gin and Affiliates Acquire Luby’s Cafeteria
Winston & Strawn LLP represented Calvin Gin and his affiliates in his acquisition of the Luby’s Cafeteria restaurant business from Luby's, Inc. (NYSE: LUB). Mr. Gin is a member of the storied Gin Family, who established The Flying Food Group by Sue Gin, which has grown to the third-largest airline catering company in North America and provides food preparation services for others, including Starbucks, throughout the United States. The purchase by the Gin affiliate (to be renamed "Luby's Restaurants Corp." following the closing of the transaction) will include 32 of the existing locations of Luby's restaurants, all in Texas, and ownership of the Luby's Cafeteria brand, which according to Mr. Gin, is “one of the iconic brands in the Texas restaurant market.” The structure of the transaction will allow Luby's to sell its real estate related to its cafeteria restaurant business to third parties and realize the related value for its shareholders. It is currently anticipated, following the closing of the transaction, that almost all employees at the 32 involved locations will be offered positions by the purchaser to remain at those store locations, employment that will likely total over 1,000 associates. The Luby's Cafeteria operations sale transaction could provide Luby's with approximately US$28.7M of value (all but a nominal amount of which will be derived from the purchaser's assumption of Luby's liabilities and the purchaser's issuance of notes to Luby's). The sale of the Luby's Cafeteria operations is another step in the execution of the previously announced plan of Luby's to sell its assets, pay its liabilities, and return the remaining cash to shareholders under the Company's previously announced plan of liquidation and dissolution approved by its shareholders on November 17, 2020.
Insights & News 209 results
Global Trade & Foreign Policy Insights
|November 12, 2024
|10+ Min Read
Winston’s Takeaways from the Final Outbound Investment Rule
On October 28, 2024, the U.S. Department of the Treasury’s (Treasury) Office of Investment Security published the final text of the Outbound Investment Security Program (the Final Rule). The Final Rule will become effective January 2, 2025. Any “Covered Transaction” entered into on or after that date will be subject to the prohibitions and affirmative legal requirements applicable to “U.S. persons” under the Final Rule. As background, the Final Rule is designed to prevent (or in some cases require notification of) U.S. investments in businesses that could benefit a Country of Concern’s semiconductor-manufacturing, artificial intelligence (AI), or quantum-computing capabilities, with a particular focus on investments that would typically be accompanied by intangible benefits such as access to investment and talent networks, enhanced access to additional financing, enhanced standing and prominence, or managerial assistance. Currently, the only designated “Country of Concern” is the People’s Republic of China, including the Special Administrative Regions of Hong Kong and Macau (collectively, China).
Non-Fungible Insights: Blockchain Decrypted
|October 9, 2024
|6 Min Read
Crypto.com’s Novel and Proactive Attempt To Force Regulatory Clarity
Regulatory uncertainty has haunted the digital asset space since its inception. The U.S. Securities and Exchange Commission (SEC) and the Commodity Futures Trading Commission (CFTC) have been engaged in a multi-year turf war over which agency has the power to regulate various aspects of digital assets.
Article
|September 20, 2024
|10 Min Read
Navigating California's SB 1047: Implications for AI Regulation and Industry Impact
This article was originally published in The Recorder. Reprinted with permission. Any opinions in this article are not those of Winston & Strawn or its clients. The opinions in this article are the authors’ opinions only.
Other Results 21 results
Law Glossary
What Is the Patent Trial and Appeal Board?
The Patent Trial and Appeal Board (PTAB) is a tribunal within U.S. Patent and Trademark Office. The PTAB oversees trial proceedings, namely: inter partes review (IPR), post-grant review (PGR), covered business method (CBM) review, and derivation proceedings. The Board also hears appeals from adverse patentability decisions by patent examiners in original applications, reissues, and reexaminations. And, while phasing out since the passage of the America Invents Act (AIA) in 2011, the PTAB is also responsible for deciding interferences. The PTAB was previously referred to as the Board of Patent Appeals and Interferences and was renamed by the AIA.
Law Glossary
A biologic—or biologic product—is a medicine made from or by living cells, typically through a series of complex processing steps. The Public Health Service Act defines a “biological product” as “a virus, therapeutic serum, toxin, antitoxin, vaccine, blood, blood component or derivative, allergenic product, protein (except any chemically synthesized polypeptide), or analogous product, or arsphenamine or derivative of arsphenamine (or another trivalent organic arsenic compound), applicable to the prevention, treatment, or cure of a disease or condition of human beings.” (42 U.S.C. § 262(i).)
Site Content
The full name of the Dodd-Frank Act is the Dodd-Frank Wall Street Reform and Consumer Protection Act. It was passed in 2010 to regulate the financial market and protect consumers from risky financial practices. The legislation and its rules cover the following: